AC Immune Releases Interim Data from Alzheimer's Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
AC Immune announced interim data from the first three cohorts of 74 patients with prodromal Alzheimer's disease in the Phase 1b/2 ABATE trial following 12 months of treatment with ACI-24 anti-amyloid beta active immunotherapy. ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance ACI-24 responses. In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema. Anti-Abeta antibody responses were detected at every dose level with a dose response. The company evaluated enhancing ACI-24 with an additional adjuvant to boost immunogenicity while the ABATE trial was ongoing. This is currently being tested in the recently initiated ABATE Cohort AD4.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACIU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACIU
Wall Street analysts forecast ACIU stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.510
Low
12.00
Averages
12.00
High
12.00
Current: 2.510
Low
12.00
Averages
12.00
High
12.00
No data
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AC Immune to Present Neurodegenerative Disease Pipeline at AAIC 2026
- Clinical Frontiers Presentation: AC Immune will showcase three significant presentations at the 2026 Alzheimer's Association International Conference, highlighting its Morphomer®-based small molecule therapies for neurodegenerative diseases, which is expected to attract industry attention and enhance the company's visibility.
- Innovative Imaging Technology: The first-in-class TDP-43 PET tracer [18F]ACI-19626 has generated encouraging early human imaging data, indicating its potential in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), potentially paving the way for future clinical applications.
- New Drug Development Progress: The novel NLRP3 inhibitor ACI-19764 has demonstrated significant efficacy in neuroinflammation models and is currently in Phase 1 clinical trials, which, if successful, will provide new options for orally delivered CNS therapies, enhancing market competitiveness.
- Multiple Therapeutic Strategies: The development of an aggregation inhibitor targeting alpha-synuclein pathology is underway, showcasing strong brain-penetrant capabilities and neuroprotective effects, further solidifying AC Immune's leadership position in the neurodegenerative disease treatment landscape.
See More
AC Immune Reports Interim Data from ACI-24 Alzheimer's Trial
- Clinical Trial Progress: AC Immune's Phase 1b/2 ABATE trial involving 74 patients with prodromal Alzheimer's disease demonstrated that ACI-24 treatment over 12 months was generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities (ARIA-E), providing positive safety data for future studies.
- Antibody Response Validation: Anti-Abeta antibody responses were detected at all dose levels in cohorts AD1 to AD3, indicating a dose-response relationship that suggests ACI-24 effectively activates immune responses across different dosages, potentially informing future treatment strategies.
- Adjuvant Testing: The ongoing AD4 cohort aims to enhance ACI-24's immunogenicity by incorporating an additional adjuvant, a strategy that could further improve treatment efficacy and strengthen the company's competitive position in the Alzheimer's treatment market.
- Collaboration with Takeda: AC Immune has secured an exclusive global option and license agreement with Takeda, receiving an upfront payment of $100 million and a milestone payment of $12 million, with potential additional development and sales milestones of up to $2.1 billion, providing substantial financial support for advancing its clinical trials and market entry.
See More
AC Immune Releases New ALS Biomarker Data from Phase 1 Trial
- Clinical Trial Progress: AC Immune SA presented preliminary data on the TDP43-PET tracer ACI-19626 at the 2026 Summit Advancing TDP43 Biomarkers, indicating higher uptake in ALS patients, suggesting its potential in diagnosing neurodegenerative diseases.
- Biomarker Exploration: TDP-43 is a key component associated with diseases like frontotemporal dementia and amyotrophic lateral sclerosis, and the development of the ACI-19626 tracer aims to visualize TDP-43 markers via PET scanning, providing new solutions for complex disease diagnoses.
- Trial Design: The Phase 1 trial for ACI-19626 consists of two parts, with the first part involving healthy patients and the second enrolling up to 30 patients with FTD, ALS, and LATE, where preliminary results show significantly higher tracer uptake in ALS patients, validating the effectiveness of the PET data.
- Pharmacokinetic Profile: The study also established the pharmacokinetic profile of ACI-19626, confirming its suitability for human brain imaging, laying the groundwork for future clinical applications.
See More
AC Immune's ACI-19626 Shows Higher PET Uptake in ALS Patients
- Clinical Trial Data: At the 2026 TDP43 Summit, AC Immune presented Phase 1 trial data for its first-in-class TDP-43 PET tracer ACI-19626, demonstrating significantly higher tracer uptake in the brains of ALS patients compared to healthy controls, particularly in key regions like the brain stem and precentral gyrus, indicating the drug's potential for early diagnosis in neurodegenerative diseases.
- Safety and Tolerability: ACI-19626 exhibited good safety and tolerability during the trial, with a dosimetry profile within accepted limits, and rapid brain uptake and washout suggest a pharmacokinetic profile suitable for human brain imaging and pharmacodynamic analysis targeting TDP-43 pathology.
- Precision Medicine Outlook: The study results underscore the importance of precision medicine for early diagnosis and intervention in multiple neurodegenerative diseases, with CEO Andrea Pfeifer emphasizing that early diagnosis is crucial for timely intervention, further validating the promise of the company's technology.
- Future Research Plans: The ongoing Phase 1 trial has completed studies in healthy volunteers and patients with genetic frontotemporal dementia, with a second phase expansion now underway, potentially including up to 30 patients with ALS, FTD, or LATE, showcasing the company's continued investment and development in the neurodegenerative disease space.
See More
AC Immune CEO Andrea Pfeifer to Retire After 23 Years
- Leadership Transition: AC Immune co-founder and CEO Andrea Pfeifer will retire at the upcoming annual general meeting, concluding her 23-year tenure, which signifies a pivotal change in the company's governance structure.
- Interim Leadership: Board Chair Martin Zügel will assume the role of interim CEO, tasked with maintaining operational stability and strategic direction while the company searches for a permanent successor, ensuring business continuity during this transition.
- Continued Involvement: Although Pfeifer is retiring, she will remain involved as an advisor, honorary chair of the board, and co-chair of the scientific advisory board, allowing her extensive industry experience to continue influencing the company's strategic decisions.
- Future Prospects: AC Immune is actively seeking a new CEO to drive ongoing innovation and growth in the neurodegenerative disease drug development space, particularly in advancing key projects like ACI-7104.
See More
AC Immune Reports Improved Q1 Financials and Pipeline Updates
- Improved Financial Performance: AC Immune reported a net loss of CHF 14.8 million for Q1, narrowing from CHF 19.0 million in the same period last year, primarily due to reduced R&D expenses, indicating effective cost management.
- Reduced R&D Expenses: The R&D expenses for the quarter were CHF 11.8 million, down from CHF 15.9 million last year, which not only alleviates financial pressure but also provides more flexibility for future research investments.
- Clinical Trial Progress: The company completed dosing of the final cohort in the ABATE trial for Alzheimer's disease, making it eligible for a $12 million milestone payment from Takeda Pharmaceuticals, which will support further research funding.
- New Drug Development Updates: The Morphomer Tau small molecule program with Eli Lilly has advanced, with eligibility for a CHF 10 million upfront payment and up to CHF 1.7 billion in milestone payments, highlighting the project's market potential and commercial value.
See More
AC Immune to Present Neurodegenerative Disease Pipeline at AAIC 2026
- Clinical Frontiers Presentation: AC Immune will showcase three significant presentations at the 2026 Alzheimer's Association International Conference, highlighting its Morphomer®-based small molecule therapies for neurodegenerative diseases, which is expected to attract industry attention and enhance the company's visibility.
- Innovative Imaging Technology: The first-in-class TDP-43 PET tracer [18F]ACI-19626 has generated encouraging early human imaging data, indicating its potential in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), potentially paving the way for future clinical applications.
- New Drug Development Progress: The novel NLRP3 inhibitor ACI-19764 has demonstrated significant efficacy in neuroinflammation models and is currently in Phase 1 clinical trials, which, if successful, will provide new options for orally delivered CNS therapies, enhancing market competitiveness.
- Multiple Therapeutic Strategies: The development of an aggregation inhibitor targeting alpha-synuclein pathology is underway, showcasing strong brain-penetrant capabilities and neuroprotective effects, further solidifying AC Immune's leadership position in the neurodegenerative disease treatment landscape.
See More
AC Immune Reports Interim Data from ACI-24 Alzheimer's Trial
- Clinical Trial Progress: AC Immune's Phase 1b/2 ABATE trial involving 74 patients with prodromal Alzheimer's disease demonstrated that ACI-24 treatment over 12 months was generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities (ARIA-E), providing positive safety data for future studies.
- Antibody Response Validation: Anti-Abeta antibody responses were detected at all dose levels in cohorts AD1 to AD3, indicating a dose-response relationship that suggests ACI-24 effectively activates immune responses across different dosages, potentially informing future treatment strategies.
- Adjuvant Testing: The ongoing AD4 cohort aims to enhance ACI-24's immunogenicity by incorporating an additional adjuvant, a strategy that could further improve treatment efficacy and strengthen the company's competitive position in the Alzheimer's treatment market.
- Collaboration with Takeda: AC Immune has secured an exclusive global option and license agreement with Takeda, receiving an upfront payment of $100 million and a milestone payment of $12 million, with potential additional development and sales milestones of up to $2.1 billion, providing substantial financial support for advancing its clinical trials and market entry.
See More
AC Immune Releases New ALS Biomarker Data from Phase 1 Trial
- Clinical Trial Progress: AC Immune SA presented preliminary data on the TDP43-PET tracer ACI-19626 at the 2026 Summit Advancing TDP43 Biomarkers, indicating higher uptake in ALS patients, suggesting its potential in diagnosing neurodegenerative diseases.
- Biomarker Exploration: TDP-43 is a key component associated with diseases like frontotemporal dementia and amyotrophic lateral sclerosis, and the development of the ACI-19626 tracer aims to visualize TDP-43 markers via PET scanning, providing new solutions for complex disease diagnoses.
- Trial Design: The Phase 1 trial for ACI-19626 consists of two parts, with the first part involving healthy patients and the second enrolling up to 30 patients with FTD, ALS, and LATE, where preliminary results show significantly higher tracer uptake in ALS patients, validating the effectiveness of the PET data.
- Pharmacokinetic Profile: The study also established the pharmacokinetic profile of ACI-19626, confirming its suitability for human brain imaging, laying the groundwork for future clinical applications.
See More
AC Immune's ACI-19626 Shows Higher PET Uptake in ALS Patients
- Clinical Trial Data: At the 2026 TDP43 Summit, AC Immune presented Phase 1 trial data for its first-in-class TDP-43 PET tracer ACI-19626, demonstrating significantly higher tracer uptake in the brains of ALS patients compared to healthy controls, particularly in key regions like the brain stem and precentral gyrus, indicating the drug's potential for early diagnosis in neurodegenerative diseases.
- Safety and Tolerability: ACI-19626 exhibited good safety and tolerability during the trial, with a dosimetry profile within accepted limits, and rapid brain uptake and washout suggest a pharmacokinetic profile suitable for human brain imaging and pharmacodynamic analysis targeting TDP-43 pathology.
- Precision Medicine Outlook: The study results underscore the importance of precision medicine for early diagnosis and intervention in multiple neurodegenerative diseases, with CEO Andrea Pfeifer emphasizing that early diagnosis is crucial for timely intervention, further validating the promise of the company's technology.
- Future Research Plans: The ongoing Phase 1 trial has completed studies in healthy volunteers and patients with genetic frontotemporal dementia, with a second phase expansion now underway, potentially including up to 30 patients with ALS, FTD, or LATE, showcasing the company's continued investment and development in the neurodegenerative disease space.
See More
AC Immune CEO Andrea Pfeifer to Retire After 23 Years
- Leadership Transition: AC Immune co-founder and CEO Andrea Pfeifer will retire at the upcoming annual general meeting, concluding her 23-year tenure, which signifies a pivotal change in the company's governance structure.
- Interim Leadership: Board Chair Martin Zügel will assume the role of interim CEO, tasked with maintaining operational stability and strategic direction while the company searches for a permanent successor, ensuring business continuity during this transition.
- Continued Involvement: Although Pfeifer is retiring, she will remain involved as an advisor, honorary chair of the board, and co-chair of the scientific advisory board, allowing her extensive industry experience to continue influencing the company's strategic decisions.
- Future Prospects: AC Immune is actively seeking a new CEO to drive ongoing innovation and growth in the neurodegenerative disease drug development space, particularly in advancing key projects like ACI-7104.
See More
AC Immune Reports Improved Q1 Financials and Pipeline Updates
- Improved Financial Performance: AC Immune reported a net loss of CHF 14.8 million for Q1, narrowing from CHF 19.0 million in the same period last year, primarily due to reduced R&D expenses, indicating effective cost management.
- Reduced R&D Expenses: The R&D expenses for the quarter were CHF 11.8 million, down from CHF 15.9 million last year, which not only alleviates financial pressure but also provides more flexibility for future research investments.
- Clinical Trial Progress: The company completed dosing of the final cohort in the ABATE trial for Alzheimer's disease, making it eligible for a $12 million milestone payment from Takeda Pharmaceuticals, which will support further research funding.
- New Drug Development Updates: The Morphomer Tau small molecule program with Eli Lilly has advanced, with eligibility for a CHF 10 million upfront payment and up to CHF 1.7 billion in milestone payments, highlighting the project's market potential and commercial value.
See More
